Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus OTICAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus OTICAIR.
ASMANEX HFA vs OTICAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min)
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Renal: 85% unchanged; biliary/fecal: 10%
Category C
Category C
Corticosteroid, Inhaled
Otic Antibiotic/Corticosteroid